University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Circ Res. 2010 Oct 1;107(7):877-87. doi: 10.1161/CIRCRESAHA.110.222968. Epub 2010 Aug 12.
Low-dose acetylsalicylic acid (aspirin) is widely used in the treatment and prevention of vascular atherothrombosis. Cardiovascular doses of aspirin also reduce systemic blood pressure and improve endothelium-dependent vasorelaxation in patients with atherosclerosis or risk factors for atherosclerosis. Aspirin can acetylate proteins, other than its pharmacological target cyclooxygenase, at lysine residues. The role of lysine acetylation in mediating the effects of low-dose aspirin on the endothelium is not known.
To determine the role of lysine acetylation of endothelial nitric oxide synthase (eNOS) in the regulation of endothelial NO production by low-dose aspirin and to examine whether the lysine deacetylase histone deacetylase (HDAC)3 antagonizes the effect of low-dose aspirin on endothelial NO production by reversing acetylation of functionally critical eNOS lysine residues.
Low concentrations of aspirin induce lysine acetylation of eNOS, stimulating eNOS enzymatic activity and endothelial NO production in a cyclooxygenase-1-independent fashion. Low-dose aspirin in vivo also increases bioavailable vascular NO in an eNOS-dependent and cyclooxygenase-1-independent manner. Low-dose aspirin promotes the binding of eNOS to calmodulin. Lysine 609 in the calmodulin autoinhibitory domain of bovine eNOS mediates aspirin-stimulated binding of eNOS to calmodulin and eNOS-derived NO production. HDAC3 inhibits aspirin-stimulated (1) lysine acetylation of eNOS, (2) eNOS enzymatic activity, (3) eNOS-derived NO, and (4) binding of eNOS to calmodulin. Conversely, downregulation of HDAC3 promotes lysine acetylation of eNOS and endothelial NO generation.
Lysine acetylation of eNOS is a posttranslational protein modification supporting low-dose aspirin-induced vasoprotection. HDAC3, by deacetylating aspirin-acetylated eNOS, antagonizes aspirin-stimulated endothelial production of NO.
小剂量乙酰水杨酸(阿司匹林)广泛用于治疗和预防血管动脉粥样硬化血栓形成。心血管剂量的阿司匹林还降低全身血压并改善动脉粥样硬化或动脉粥样硬化危险因素患者的内皮依赖性血管舒张。阿司匹林可以乙酰化除其药理学靶标环氧化酶以外的蛋白质在赖氨酸残基上。小剂量阿司匹林对内皮的作用中赖氨酸乙酰化的作用尚不清楚。
确定内皮型一氧化氮合酶(eNOS)赖氨酸乙酰化在调节低剂量阿司匹林诱导的内皮一氧化氮产生中的作用,并研究赖氨酸去乙酰化酶组蛋白去乙酰化酶(HDAC)3 是否通过逆转功能关键 eNOS 赖氨酸残基的乙酰化来拮抗低剂量阿司匹林对内皮一氧化氮产生的作用。
低浓度的阿司匹林诱导 eNOS 的赖氨酸乙酰化,以环氧化酶-1 独立的方式刺激 eNOS 酶活性和内皮一氧化氮产生。体内低剂量阿司匹林也以 eNOS 依赖性和环氧化酶-1 独立的方式增加生物可利用的血管一氧化氮。低剂量阿司匹林促进 eNOS 与钙调蛋白结合。牛 eNOS 钙调蛋白自动抑制结构域中的赖氨酸 609 介导阿司匹林刺激的 eNOS 与钙调蛋白结合和 eNOS 衍生的一氧化氮产生。HDAC3 抑制阿司匹林刺激的(1)eNOS 赖氨酸乙酰化,(2)eNOS 酶活性,(3)eNOS 衍生的 NO 和(4)eNOS 与钙调蛋白的结合。相反,下调 HDAC3 促进 eNOS 的赖氨酸乙酰化和内皮一氧化氮生成。
eNOS 的赖氨酸乙酰化是一种支持低剂量阿司匹林诱导的血管保护的翻译后蛋白质修饰。HDAC3 通过去乙酰化阿司匹林乙酰化的 eNOS,拮抗阿司匹林刺激的内皮一氧化氮产生。